Wockhardt Medicines Profile
Key Indicators
-
Authorised Capital
₹ 1.00 M
as on 23-10-2024
-
Paid Up Capital
₹ 0.50 M
as on 23-10-2024
- Company Age 5 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
-
Revenue
%
(FY 2023)
-
Profit
-202.77%
(FY 2023)
-
Ebitda
-202.32%
(FY 2023)
-
Net Worth
-201.66%
(FY 2023)
-
Total Assets
2371.43%
(FY 2023)
About Wockhardt Medicines
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Stephen Dsouza, Sujatha Shetty, and Janet Gonsalves serve as directors at the Company.
-
CIN/LLPIN
U74999MH2019PLC322942
-
Company No.
322942
-
Company Classification
Public Limited Indian Non-Government Company
-
Incorporation Date
25 Mar 2019
-
Date of AGM
05 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Company Details
-
Location
Mumbai, Maharashtra, India
-
Telephone
-
Email Address
-
Website
-
Social Media
Who are the key members and board of directors at Wockhardt Medicines?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Stephen Dsouza
|
Director | 25-Mar-2019 | Current |
|
Sujatha Shetty
|
Director | 30-Mar-2021 | Current |
|
Janet Gonsalves
|
Director | 01-Jun-2022 | Current |
Financial Performance and Corporate Structure Insights of Wockhardt Medicines.
Wockhardt Medicines Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 202.77% decrease in profit. The company's net worth observed a substantial decline by a decrease of 201.66%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Wockhardt Medicines?
In 2023, Wockhardt Medicines had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
-
Sharanya Chemicals And Pharmaceuticals Private LimitedActive 25 years 8 months
Stephen D'souza and Sujatha Shetty are mutual person
-
Banneret Trading Private LimitedActive 16 years 8 months
Stephen D'souza and Janet Gonsalves are mutual person
-
Wockhardt Holdings LimitedActive 27 years 6 months
Stephen D'souza, Sujatha Shetty and 1 more are mutual person
-
-
Wockhardt Infrastructure Development LimitedActive 33 years 10 months
Sujatha Shetty is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Wockhardt Medicines?
Unlock and access historical data on people associated with Wockhardt Medicines, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Wockhardt Medicines, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Wockhardt Medicines's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
